导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.73% | 3484/4773 |
| 近一周 | -1.87% | 3043/5465 |
| 近一月 | -2.56% | 1744/5421 |
| 近一季 | -3.73% | 1674/5231 |
| 近半年 | -4.35% | 2794/4920 |
| 近一年 | -6.34% | 3205/4394 |
| 近两年 | 36.99% | 2034/2954 |
| 近三年 | 27.05% | 1218/2253 |
| 成立以来 | 32.79% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.52% 3854/4961 |
1.89% 2982/5312 |
- - |
- - |
| 2025 | 24.00% 1822/4813 |
7.49% 495/3635 |
2.35% 1626/4076 |
15.95% 2748/4524 |
-2.79% 3205/4813 |
| 2024 | 16.69% 777/3463 |
0.27% 1007/2808 |
3.59% 263/3014 |
15.12% 1807/3129 |
-2.40% 2068/3463 |
| 2023 | -9.80% 1231/2656 |
2.44% 1349/2280 |
-2.74% 646/2385 |
-4.89% 1248/2515 |
-4.81% 1184/2655 |
| 2022 | -13.81% 344/2207 |
-11.53% 523/1919 |
7.13% 525/2016 |
-14.71% 1136/2113 |
6.62% 355/2208 |
| 2021 | -8.71% 1055/1822 |
0.36% 298/1255 |
1.64% 1039/1330 |
-9.38% 1176/1466 |
-1.24% 1338/1822 |
| 2020 | 25.23% 620/1250 |
-7.77% 571/1028 |
11.94% 708/1067 |
5.96% 883/1164 |
14.46% 273/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成中华沪深港300指数(LOF)A VS. 长安沪深300非周期A(740101) |